Abstract

The aim of this study was to investigate diagnostic and prognostic values of Nterminal proC type natriuretic peptide in patients with stage II – IV chronic obstructive pulmonary disease (COPD) (GOLD, 2011). Methods. Patients with stage II – IV COPD (n = 47; 44 males, mean age, 59.49 ± 0.63 years; disease duration, 13.7 ± 0.63 years; smoking history, 23.09 ± 0.93 packyears; body mass index, 27.22 ± 9.06 kg / m–2) were involved in the study. The patients were divided according to presence or absence of pulmonary hypertension (PH): patients without PH (n = 21; systolic pulmonary artery pressure (sPAP) < 40 mmHg), patients with mild PH (n = 16, sPAP 40 – 55 mmHg) and patients with severe PH (n = 10; sPAP > 55 mmHg). Results. NTproCNP levels differed significantly between patients without PH (1.42 ± 0.03 pg / mL), patients with mild PH (4.14 ± 0.51 pg / mL) and patients with severe PH (5.26 ± 0.21 pg / mL) (p1–2 = 0.001; p2–3 = 0.001; p1–3 < 0.001). sPAP was related to NTproCNP level (r = 0.53; p < 0.05). Conclusion. NTproCNP had a high diagnostic value for predicting severe and nonsevere PH in COPD patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.